Childhood-onset Idiopathic Nephrotic Syndrome – Market outlook, Epidemiology, Competitive Landscape and Market Forecast Report – 2020 To 2030
Nephrotic syndrome (NS) is one of the most common chronic kidney diseases in children and is characterized by significant proteinuria, hypoalbuminemia, and edema. The primary, idiopathic form of NS, which accounts for a large portion of NS, often occurs due to a stale infection in infancy/early childhood. The current recommended treatment is cortisone therapy over multiple weeks. Youth NS can be congenital, presenting within the first three months of life. In these children, there is usually a genetic mutation affecting either the podocyte of the glomerular basement membrane, although rarely it can be associated with congenital infections such as cytomegalovirus. Apart from the hereditary form of nephrotic syndrome, many underlying aetiologies can cause nephrotic syndrome, including glomerular disorders, vasculitides, infections, toxins, malignancy, genetic mutations, and most commonly, unknown.
The
incidence of NS varies in different population groups and is currently reported
to be 2 to 7 children in the USA. In several European studies, South Asian
children were reported to have a higher incidence of NS than the European
population.
The competitive
landscape of Childhood-onset Idiopathic Nephrotic Syndrome includes country-specific
approved and pipeline therapies. Any asset/product-specific designation or
review and Accelerated Approval are tracked and supplemented with analyst
commentary.
KOLs insights of Childhood-onset
Idiopathic Nephrotic Syndrome across 8 MM market from the center of Excellence/
Public/ Private hospitals participated in the study. Insights around current
treatment landscape, epidemiology, clinical characteristics, future treatment
paradigm, and Unmet needs.
Childhood-onset
Idiopathic Nephrotic Syndrome Market Forecast:
Patient Based Forecast Model (MS. Excel Based Automated Dashboard) which Data
Inputs with sourcing, Market Event, and Product Event, Country specific
Forecast Model, Market uptake and patient share uptake, Attribute Analysis,
Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.
S. No Asset Company Stage
1 Obinutuzumab Genentech Phase 2
2 Abatacept Bristol-Myers
Squibb Phase 2
Comments
Post a Comment